A Study of 18F-AV-45 in Healthy Volunteers
- Registration Number
- NCT01564706
- Lead Sponsor
- Avid Radiopharmaceuticals
- Brief Summary
This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
- Able to lie still on the imaging table for periods up to 1 hour
Exclusion Criteria
- Radiation exposure for experimental purposes within the last year
- Claustrophobic or otherwise unable to tolerate the imaging procedure
- Medical condition or surgical history that would confound evaluation
- Current clinically significant cardiovascular disease
- Received an investigational medication within the last 30 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Healthy Volunteers florbetapir F 18 Healthy male or female subjects, between 18 and 85 years of age.
- Primary Outcome Measures
Name Time Method Whole Body Radiation Dosimetry 0-380 min after injection Radiation dose values (millisieverts/megabecquerel \[mSv/MBq\]) for regions of the whole body. Target organs included the adrenals, brain, breasts, gall bladder wall, lower large intestine wall, small intestine wall, stomach wall, upper large intestine wall, heart wall, kidneys, liver, lungs, muscle, ovaries, pancreas, osteogenic cells, skin, spleen, testes, thymus, thyroid, urinary bladder wall, uterus, and total body.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇺🇸Jenkintown, Pennsylvania, United States